INOCSA

TO THE SPANISH SECURITIES MARKET COMMISSION

Pursuant to article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Inoc, S.A. ("**Inocsa**"), hereby announces the following,

OTHER RELEVANT INFORMATION

In connection with the voluntary public tender offer (the "**Offer**") launched by Inocsa for all the shares representing the share capital of Grupo Catalana Occidente, S.A. ("**GCO**"), which was authorized by the Spanish Securities Market Commission (the "**CNMV**") on 29 October 2025 and whose result has been published by the CNMV today, Inocsa reports the following:

1. Exercise of the squeeze-out right

The Offer has been accepted by shareholders holding 42,950,434 shares, representing 94.27% of the shares to which the Offer was addressed and 35.79% of GCO's share capital. As a result, the direct and indirect shareholding of Co Sociedad de Gestión y Participación, S.A. ("**CO**"), Inocsa's parent company, will amount to 117,391,476 GCO shares, representing 97.83% of GCO's share capital, following the settlement of the Offer.

Settlement of the portion of the Offer corresponding to the cash consideration is scheduled for 9 December 2025, whereas settlement of the portion corresponding to the exchange consideration is scheduled for 10 December 2025. These dates correspond to two and three trading days, respectively, after the publication of the result of the Offer in the Stock Exchange Bulletins, which will take place on 5 December 2025.

Based on the level of acceptances received, the requirements set out in article 116 of Law 6/2023 and article 47 of Royal Decree 1066/2007 for the exercise of the squeeze-out and sell-out rights have been met.

In view of the foregoing, and in accordance with the terms set out in the prospectus of the Offer, the board of directors of Inocsa has resolved to exercise the squeeze-out right in respect of all GCO shares that are not held directly or indirectly by CO following settlement of the Offer. The consideration will be paid in cash and will be equal to the consideration offered in the Offer, namely, EUR 49.75 per GCO share, which shall be adjusted downwards by the gross amount per share of any distributions (including dividends, reserves or any other distribution, whether ordinary, extraordinary, interim or final) that may be paid to GCO shareholders prior to the date on which the squeeze-out transaction is settled, in accordance with section 3.7 of the prospectus of the Offer.

In this regard, Inocsa reports that it is analysing the possibility of proposing to the board of directors of GCO the distribution of an extraordinary dividend for, among others, making payment in December 2025 of the first repayment installment of the principal amount of the financing of the Offer and, eventually, of a voluntary partial prepayment of the same.

However, as of the date of this communication, no decision has been taken in relation to such potential dividend—neither with respect to its possible approval nor, where applicable, its amount—. Should such dividend be finally approved by GCO, it would be duly disclosed by GCO through its usual corporate reporting channels. In any event, it is noted that any potential dividend that may be approved by GCO would not be paid to those GCO shareholders who have accepted the Offer, except for those having accepted the Offer by means of the exchange consideration and keeping a remainder of shares of GCO due to the application of the exchange ratio.

With respect to the squeeze-out transaction, Inocsa reports that it has resolved to set **30 December 2025** as the date of the transaction, with settlement therefore taking place on 2 January 2026. The execution of the squeeze-out transaction will result in the delisting of all GCO shares. The delisting of GCO shares will become effective upon settlement of the squeeze-out transaction.

The squeeze-out will be carried out in accordance with the procedures described in section 3.7 of the prospectus of the Offer.

For the proper execution and completion of the squeeze-out, Inocsa will request that the CNMV resolve to suspend trading of GCO shares on the Barcelona and Madrid Stock Exchanges after market close on 15 December 2025, and that trading remains suspended until definitive delisting occurs.

GCO shareholders wishing to require Inocsa to purchase their shares prior to the date of the squeeze-out may do so in accordance with article 116 of Law 6/2023 and article 48 of Royal Decree 1066/2007, as described in the prospectus of the Offer. Shareholders are reminded, however, that in the squeeze-out transaction, all expenses derived from the sale and settlement of the shares will be borne by Inocsa, whereas in the event shareholders exercise the sell-out right, such expenses will be borne by the selling shareholders. Settlement of the sell-out transactions will take place within the same period applicable to settlement of the Offer, counted from the date of receipt of each sell-out request. Should the settlement of any such sell-out request, based on its date of receipt, fall after the settlement date of the squeeze-out transaction, the request shall be deemed ineffective and the corresponding shares shall be included in the squeeze-out transaction.

Finally, shareholders are informed that, as soon as practicable and in any event within five trading days from today, Inocsa will make public the terms and features of the squeeze-out in accordance with article 48 of Royal Decree 1066/2007 and the provisions set out in the prospectus of the Offer. Attached hereto is the text of the squeeze-out announcement in English.

2. Execution of the share capital increase

Inocsa also reports that the resolutions adopted at the ordinary general shareholders' meeting held on 30 April 2025 under items Eight ("*Reclassification of existing shares as Class A shares and creation of a new Class B of shares. Subsequent amendment of article 5 of the bylaws and inclusion of a new article 5 bis*"), Nine ("*Creation of an ancillary service affecting Class B shares and inclusion of a new article 6 bis in the bylaws*") and Ten ("*Amendment of *the share transfer regime. Subsequent amendment of article 7 of the bylaws and inclusion of a new article 7 bis*") have become fully valid and effective upon fulfilment of all conditions to which they were subject.

Furthermore, in view of the result of the Offer under the exchange consideration alternative, the board of directors of Inocsa has resolved to execute the share capital increase through non-cash contributions approved under item Seven of the agenda of the ordinary general shareholders' meeting held on 30 April 2025 ("*Approval of a share capital increase for a maximum nominal amount to be determined by the general meeting, through the issuance of new Class B shares, for the purpose of delivering them to the shareholders of Grupo Catalana Occidente, S.A. who tender their shares in the voluntary takeover bid launched by the Company under the exchange consideration alternative. Delegation of authority to the board of directors to determine the terms and conditions of the share capital increase not approved by the general meeting*"), through the issuance of 112,415 Class B shares of Inocsa with a nominal value of EUR 6.01 and an issue premium of EUR 2,180.23 per share (the "**New Inocsa Shares**"). The total nominal amount of the share capital increase is 675,614.15 euros, and the total issue premium amounts to 245,090,555.45 euros, resulting in an aggregate amount of 245,766,169.60 euros for the increase.

On 10 December 2025, the notarial deed of share capital increase will be executed, accompanied by the certificate issued by Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. ("**Iberclear**") regarding the GCO shares tendered under the exchange consideration alternative and to be contributed in the share capital increase. The issuance, subscription, payment and registration of the New Inocsa Shares, in the company's register of registered shares, in the name of the GCO shareholders who have accepted the exchange consideration alternative will also be completed on such date. On that same date, Inocsa will submit the notarial deed of share capital increase to the Madrid Commercial Registry for registration, will send an attested copy thereof to Iberclear together with a certificate of the company's share register, and will proceed with settlement of the portion of the Offer corresponding to the exchange consideration alternative. Inocsa undertakes to use its best efforts to ensure that registration of the share capital increase with the Madrid Commercial Registry takes place before the date of the squeeze-out transaction, that is, 30 December 2025.

In Madrid, on 5 December 2025.

Inoc, S.A.

____

Mr. Francisco José Arregui Laborda
Secretary director and attorney-in-fact

INOCSA

Annex

[*see following page*]

NOTICE OF THE CHARACTERISTICS OF THE SQUEEZE-OUT FOLLOWING THE VOLUNTARY TAKEOVER BID LAUNCHED BY INOC, S.A. FOR ALL THE SHARES REPRESENTING THE SHARE CAPITAL OF GRUPO CATALANA OCCIDENTE, S.A.

This notice is published pursuant to article 48.5 of Royal Decree 1066/2007, of 27 July, on the regime governing takeover bids ("**Royal Decree 1066/2007**"), and sets out the characteristics of the squeeze-out resulting from the voluntary takeover bid launched by Inoc, S.A. ("**Inocsa**") for all the shares representing the share capital of Grupo Catalana Occidente, S.A. ("**GCO**"), which was authorized by the Spanish Securities Market Commission (the "**CNMV**") on 29 October 2025 (the "**Offer**") and whose result was published by the CNMV on 5 December 2025 and in the official stock exchange bulletins on 5 December 2025.

1. SQUEEZE-OUT AND SELL-OUT RIGHTS

In accordance with article 48.3 of Royal Decree 1066/2007 and section 3.7 of the prospectus of the Offer (the "**Prospectus**"), Inocsa reported through a communication of other relevant information dated 5 December 2025 that the requirements for the exercise of the squeeze-out and sell-out rights had been met and that it had resolved to exercise the squeeze-out right, which will enable Inocsa to acquire all shares of GCO that are not held directly or indirectly by Co Sociedad de Gestión y Participación, S.A. after settlement of the Offer.

2. CONSIDERATION FOR THE SQUEEZE-OUT

The consideration will be paid in cash and will be equal to the consideration offered in the cash alternative of the Offer, namely, EUR 49.75 per GCO share, which shall be adjusted downwards by the gross amount per share of any distributions (including dividends, reserves or any other distribution, whether ordinary, extraordinary, interim or final) that may be paid to GCO shareholders prior to the date on which the squeeze-out transaction is settled.

3. DATE OF THE TRANSACTION AND SETTLEMENT DATE

The squeeze-out transaction will take place on 30 December 2025. Settlement of the transaction will take place on the second trading day following the transaction date, that is, on 2 January 2026.

4. GUARANTEE

Inocsa has submitted to the CNMV documentation evidencing the constitution of the guarantee ensuring compliance with its payment obligations arising from the exercise of the squeeze-out, in accordance with article 48.4 of Royal Decree 1066/2007. The guarantee consists of an on-demand guarantee issued by CaixaBank, S.A. for an amount of 129,774,069 euros, corresponding to the total aggregate consideration payable as a result of the squeeze-out.

5. PROCEDURE FOR EXECUTION OF THE SQUEEZE-OUT

All entities holding GCO shares in custody must execute the sale of such shares to Inocsa on the transaction date (i.e., 30 December 2025) in accordance with the procedure established by Iberclear. Settlement and payment of the consideration will be carried out in accordance with article 48.4 of Royal Decree 1066/2007 and will therefore take place on 2 January 2026.

If the GCO shares subject to the squeeze-out are seized pursuant to administrative or judicial decisions, or are encumbered by charges, liens, limited real rights or financial collateral, such shares will be transferred free of any such encumbrances, which will instead attach to the price paid by Inocsa for the purchase. The custodian will be required to hold the sale price in deposit and notify the relevant authority or holders of the encumbrances. Any portion of the sale price not required to satisfy the relevant secured obligations must be made immediately available to the shareholder.

The acquisitions under the squeeze-out will be supervised and settled by CaixaBank, S.A.

6. EXPENSES RELATED TO THE SQUEEZE-OUT

All expenses arising from the sale and settlement of the shares will be borne by Inocsa.

7. DELISTING OF GCO

In accordance with article 48.10 of Royal Decree 1066/2007, the squeeze-out will result in the delisting of GCO shares, which will be effective upon settlement of the transaction.

For the proper execution of the squeeze-out, Inocsa will request that the CNMV resolve to suspend trading in GCO shares on the Barcelona and Madrid Stock Exchanges after the market close on 15 December 2025, and that trading remain suspended until definitive delisting occurs.